Shanghai Ruotuo Biotechnology Co. Ltd. has patented antibody-drug conjugates (ADCs) comprising bispecific antibodies targeting epidermal growth factor receptors (EGFR; ERBB; HER) and receptor tyrosine-protein kinase erbb-3 (ERBB3; HER3) linked to a cytotoxic drug through a linker intended for use in the treatment of cancer.

Shanghai Ruotuo Biotechnology Co. Ltd. has identified antibody-drug conjugates consisting of antibodies targeting HER2 (erbB2) covalently linked to camptothecin derivatives through a linker reported to be useful for the treatment of cancer.